ARSL

Across TCGA pan-cancer cohorts, ARSL mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARSL data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARSL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARSL expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, UCEC, and GBM are the cancer types where ARSL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	1.000	0.716	.006	23	view →
UCEC	OS	Tertile	All	1.000	0.861	.016	6	view →
GBM	OS	Median	All	0.627	0.265	.022	4	view →
CCRCC	DFS	Tertile	All	0.879	0.561	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARSL–HNSC (DFS)

Open the HNSC breakdown →